BCIQ Profiles

Company Profile Report
BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.
0603 Data Byte het covid vaccines
BioCentury & Flourish

Product Development

Trials mixing and matching COVID-19 vaccines: Data Byte

Jun 4, 2021 | 2:14 AM GMT

Interest in mixing different COVID-19 vaccines in prime-boost regimens is on the rise due to supply issues and safety concerns. At least 12 ongoing trials were designed to test combinations of vaccines for prime and boost shots, and at least three others include secondary boosters of different vaccines, according to BioCentury’s Clinical Trial Dashboard.

Most of the trials designed to test heterologous prime-boost regimens (shown below) are pairing vaccines already authorized for emergency use, with only two of the trials including non-authorized vaccines.

One of the two trials is testing an additional boost with mRNA-1273.351, which targets the beta SARS-CoV-2 variant (B.1.351), after two doses of Moderna COVID-19 Vaccine, the authorized vaccine from Moderna Inc. (NASDAQ:MRNA). The other is a Phase I trial pairing a new mRNA vaccine and a new viral vector vaccine from Gritstone Oncology Inc.

At least three trials are testing a second boost after a standard homologous vaccine schedule (not shown in table), all of which are adding on non-authorized vaccines.

BioCentury’s analysis included ongoing Phase I-IV trials and those without an FDA-defined phase in the ClinicalTrials.gov and ChiCTR.org.cn registries.

How to gain access

Continue reading with a
two-week free trial.